- SEK206.18m
- -SEK60.82m
- SEK26.00m
Brief: Orexo Sees 2024 Buprenorphine/Naloxone Market To Grow 2-5%
Brief: Orexo Q1 EBIT SEK -4.7 Million
Brief: Orexo AB Says James Noble Was Elected As Chairman Of Board
Brief: Orexo Extends Patent Protection In US
Brief: Orexo Issues Senior Secured Callable Floating Rate Social Bonds Of SEK 500 M
Brief: Orexo Plans Social Bonds Issuance, Tender Offer For Existing Bonds
Brief: Orexo, SOBI Agree To Advance Feasibility Study With Amorphox
Brief: Orexo Sees Positive EBITDA In 2024
Brief: Orexo Q4 EBIT SEK -8.6 Million
Brief: Orexo Announces FDA Acceptance Of New Drug Application Filing For OX124
Brief: Orexo To Launch Second Pharma Product In U.S Late 2024 Or Early 2025
Brief: Orexo Q3 EBIT SEK -28.6 Million
Brief: Orexo Posts Data From Modia Study On Impact On Use Of Illicit Opioids
Brief: Orexo Submits New Drug Application To FDA For Ox124
Brief: Orexo Secures Patent Protection In U.S. For Ox640
Brief: Orexo's Patent Win For Zubsolv Appealed
Brief: Orexo Expects Reduced Opex In H2 Compared To H1
Brief: Orexo Q2 EBIT SEK -12.9 Million
Brief: Orexo Wins Patent Litigation For Zubsolv® In The Us